Database

Startups

Main Industry
Biotechnology
Main Product/Service
Nebulum’s flagship offering is its 3D Whole-Tissue Imaging service, which encompasses sample preparation (fixation, delipidation, and refractive index matching), high-resolution lightsheet microscopy, and tailored image analysis (e.g., cell counting, neur
Founded Year
2020
Unified Business No.
83761687
Status
Active
Number of Employees
0
Total Paid-in Capital
79,414,632 (NT$)
Location of Company
Taiwan , Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself. Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
About the Company
Nebulum Technologies, based in Taipei, is a pioneering bio-imaging startup that specializes in 3D whole-tissue imaging and high-precision data analytics. Using proprietary tissue-clearing, immunolabeling, and lightsheet microscopy techniques, the company delivers continuous, high-fidelity three-dimensional images of biological tissues to research institutions, pharmaceutical companies, and clinical diagnosticians — accelerating progress in precision medicine and biomedical research.



more ↓

Similar Companies

BIOLEGEND TAIWAN INC.

1. Antibodies and Reagents
2. Apoptosis and Cell Health Reagents
3. Buffers and Chemical Probes
4. Clinical | Analyte Specific Reagents (ASR)
5. Isotype Controls
6. Magnetic Separation - MojoSort™
7. Non-Human Primate Antibodies
8. Recombinant Proteins, C

Fluidiconic Biotechnology Co., Ltd.

Fluidiconic Biotechnology develops tumor microenvironment chips and culture analysis platforms to support faster and more accurate anticancer drug development. Its TMoC series simulates molecular gradients from blood vessels to the tumor core, preserving tumor genetics and drug responses. Combined with the MedSelect platform and BioVision software, the system enables high-throughput dynamic culture, automated imaging, and visualized analysis, while the BioLab platform provides customized chip integration and ODM services for R&D teams.
:::
回頁面最頂端